Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
23595944
DOI
10.1136/jnnp-2012-304740
PII: jnnp-2012-304740
Knihovny.cz E-resources
- Keywords
- Clinical Neurology, Mri, Multiple Sclerosis, Neurobiology, Neuroradiology,
- MeSH
- Adjuvants, Immunologic therapeutic use MeSH
- Early Medical Intervention MeSH
- Cholesterol blood MeSH
- Demyelinating Diseases blood drug therapy MeSH
- Adult MeSH
- Cholesterol, HDL blood MeSH
- Body Mass Index MeSH
- Injections, Intramuscular MeSH
- Interferon beta-1a MeSH
- Interferon-beta therapeutic use MeSH
- Calcifediol blood MeSH
- Cohort Studies MeSH
- Smoking adverse effects blood MeSH
- Cholesterol, LDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Magnetic Resonance Imaging MeSH
- Young Adult MeSH
- Brain drug effects pathology MeSH
- Prospective Studies MeSH
- Multiple Sclerosis blood diagnosis drug therapy MeSH
- Thyrotropin blood MeSH
- Thyroxine blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Cholesterol MeSH
- Cholesterol, HDL MeSH
- Interferon beta-1a MeSH
- Interferon-beta MeSH
- Calcifediol MeSH
- Cholesterol, LDL MeSH
- Thyrotropin MeSH
- Thyroxine MeSH
OBJECTIVES: To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were obtained in pretreatment serum from 135 high risk patients with CIS (≥ 2 brain MRI lesions and ≥ 2 oligoclonal bands) enrolled in the Observational Study of Early Interferon β-1a Treatment in High Risk Subjects after CIS study (SET study), which prospectively evaluated the effect of intramuscular interferon β-1a treatment following the first demyelinating event. Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status and body mass index were also obtained. Clinical and MRI assessments were obtained within 4 months of the initial demyelinating event and at 6, 12 and 24 months. RESULTS: The time to first relapse and number of relapses were not associated with any of the lipid profile variables. Higher LDL-C (p=0.006) and TC (p=0.001) levels were associated with increased cumulative number of new T2 lesions over 2 years. Higher free thyroxine levels were associated with lower cumulative number of contrast-enhancing lesions (p=0.008). Higher TC was associated as a trend with lower baseline whole brain volume (p=0.020). Higher high density lipoprotein was associated with higher deseasonalised 1,25-dihydroxy vitamin D3 (p=0.003) levels and a trend was found for deseasonalised 25-hydroxy vitamin D3 (p=0.014). CONCLUSIONS: In early multiple sclerosis, lipid profile variables particularly LDL-C and TC levels are associated with inflammatory MRI activity measures.
References provided by Crossref.org
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
MRI correlates of disability progression in patients with CIS over 48 months
